Kim DW - Search Results

1

Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.

Kim DW, Tan EY, Jin Y, Park S, Hayes M, Demirhan E, Schran H, Wang Y. Kim DW, et al. Br J Clin Pharmacol. 2011 Feb;71(2):199-206. doi: 10.1111/j.1365-2125.2010.03810.x. Br J Clin Pharmacol. 2011. PMID: 21219400 Free PMC article.

2

Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.

Kim SH, Kim D, Kim DW, Goh HG, Jang SE, Lee J, Kim WS, Kweon IY, Park SH. Kim SH, et al. Among authors: kim dw, kim d, kim ws. Hematol Oncol. 2009 Dec;27(4):190-7. doi: 10.1002/hon.894. Hematol Oncol. 2009. PMID: 19274615

3

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.

Goh HG, Kim YJ, Kim DW, Kim HJ, Kim SH, Jang SE, Lee J, Kim D, Kim WS, Park SH, Kweon IY. Goh HG, et al. Among authors: kim yj, kim hj, kim dw, kim sh, kim d, kim ws. Leuk Lymphoma. 2009 Jun;50(6):944-51. doi: 10.1080/10428190902926973. Leuk Lymphoma. 2009. PMID: 19479613

4

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.

Kim WS, Kim D, Kim DW, Kweon IY, Kim SH, Goh HG, Park SH, Lee J. Kim WS, et al. Among authors: kim dw, kim d, kim sh. Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918. Hematol Oncol. 2010. PMID: 19768693

5

Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation.

Kim D, Goh HG, Kim SH, Choi SY, Park SH, Jang EJ, Kim DW. Kim D, et al. Among authors: kim dw, kim sh. Int J Hematol. 2012 Jul;96(1):47-57. doi: 10.1007/s12185-012-1093-y. Epub 2012 May 19. Int J Hematol. 2012. PMID: 22610512

6

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW. Kim SH, et al. Among authors: kim h, kim hj, kim yk, kim dw, kim dy, kim ja. Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4. Haematologica. 2014. PMID: 24705186 Free PMC article. Clinical Trial.

7

Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.

Kim D, Kim DW, Cho BS, Goh HG, Kim SH, Kim WS, Lee J, Kweon IY, Park SH, Yoon JH, Kim ND, Chun H. Kim D, et al. Among authors: kim dw, kim sh, kim nd, kim ws. Leuk Res. 2009 Sep;33(9):1260-5. doi: 10.1016/j.leukres.2008.12.017. Epub 2009 Feb 6. Leuk Res. 2009. PMID: 19201023

8

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.

Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP. Mahon FX, et al. Among authors: kim dw. Ann Intern Med. 2018 Apr 3;168(7):461-470. doi: 10.7326/M17-1094. Epub 2018 Feb 20. Ann Intern Med. 2018. PMID: 29459949 Clinical Trial.

9

Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.

Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, Altamura HK, Hiwase DK, Yeung DT, Kim DW, Branford S, Hughes TP. Shanmuganathan N, et al. Among authors: kim dw. Blood. 2021 Mar 4;137(9):1196-1207. doi: 10.1182/blood.2020005514. Blood. 2021. PMID: 32871588 Free article.

10

Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.

Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY, Park JE, Jeon HR, Oh YJ, Kim HJ, Kim YK, Park JS, Jeong SH, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Mauro MJ, Kim DW. Lee SE, et al. Among authors: kim h, kim hj, kim yk, kim dw, kim sh, kim dy, kim ja. Am J Hematol. 2013 Jun;88(6):449-54. doi: 10.1002/ajh.23427. Epub 2013 Mar 28. Am J Hematol. 2013. PMID: 23440689 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,163 results

Search Page